Reckitt has made a good start to the first quarter of 2013... As yet there has been a limited impact on Reckitt Benckiser Pharmaceuticals following the launch of generics in March with the division also benefiting from the sell-in of film into the US wholesalers, resulting in revenue growth ahead of expectations.
KEITH BOWMAN HARGREAVES LANSDOWN
Despite newly introduced generic competition for its highly profitable pharmaceuticals business, the update has broadly reassured investors... In all, despite the company’s clear defensive attributes, concerns persist, with analyst opinion for now denoting a weak ‘hold’.
DARREN SHIRLEY SHORE CAPITAL
Whilst we are increasingly encouraged by the performance of Reckitt’s core business, and believe the focus on heath & hygiene will support growth in the medium to long term, our analysis suggests Reckitt Pharmaceuticals arm will hold back earnings per shares growth for the short to medium term.